Ipsen S.A. (IPSEF)
OTCMKTS
· Delayed Price · Currency is USD
120.55
-3.86 (-3.10%)
At close: Feb 7, 2025
Ipsen Employees
Ipsen had 5,358 employees as of December 31, 2024. The number of employees increased by 33 or 0.62% compared to the previous year.
Employees
5,358
Change (1Y)
33
Growth (1Y)
0.62%
Revenue / Employee
$690,686
Profits / Employee
$66,837
Market Cap
9.78B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 2,931 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 413 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| Silence Therapeutics | 109 |
| Longduoduo Company | 49 |
Ipsen News
- 27 days ago - Ipsen S.A. 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 27 days ago - Ipsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Ipsen S.A. Non-GAAP EPS of €10.27, revenue of €3.4B; initiates FY25 outlook - Seeking Alpha
- 3 months ago - Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions - Seeking Alpha
- 5 months ago - Ipsen S.A. reports Q3 results; raises FY24 guidance - Seeking Alpha
- 5 months ago - Eton Pharmaceuticals to buy Increlex product from Ipsen - Seeking Alpha
- 6 months ago - Ipsen's Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease - Benzinga
- 6 months ago - Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade - Benzinga